AGP Executive Report
Last update: 8 hours agoDrug Development: Ono Pharmaceutical has secured rights to Biohaven’s IgG-degrader drugs in Taiwan and other Asian markets in a deal worth up to US$100 million. The lead candidate is in Phase III testing for Graves’ disease. Mental Health: Taiwan ranked 83rd of 84 places for adults aged 18–34 in a global mind-health report, based on measures including mood, resilience and cognition. Flu Season: Taiwan is seeing a one-year high in flu deaths and severe cases, while 1.06 million people have been vaccinated. Health Technology: NTT Data and Taiwan’s TwHealth Nexus plan to explore AI and data services for healthcare providers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.